CD4+ TH1 cells generated by ii-padre DNA at prime phase are important to induce effectors and memory CD8+ T cells

Journal of Immunotherapy

Volumn 33, Issue 5, 2010, Pages 510-522

  Park, Jae Yeo ^a   Jin, Dong Hoon ^a,b   Lee, Chang Min ^c   Jang, Min Ja ^a   Lee, Sun Young ^a   Shin, Hyo Seon ^a   Chung, Yoon Hee ^a   Kim, Kyung Yong ^a   Kim, Sung Su ^a   Lee, Won Bok ^a   Shin, Yong Kyoo ^a   Lee, Wang Jae ^a,b   Park, Yeong Min ^a,c,d   Kim, Daejin ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d National Research Laboratory of Dendritic Cells Differentiation and Regulation   (United States)

Author keywords

Bcl xL; DNA vaccine; E7; Ii PADRE; Prime boost

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; B LYMPHOCYTE ANTIGEN; CANCER VACCINE; HLA ANTIGEN CLASS 2; HYBRID PROTEIN; INVARIANT CHAIN; MALARIA VACCINE; PADRE 45; PROTEIN BCL X; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; IN VIVO STUDY; LUNG CANCER; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANIMAL; C57BL MOUSE; CELL COMMUNICATION; CYTOTOXICITY; DRUG EFFECTS; GENETICS; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; PROTEIN ENGINEERING;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BCL-X PROTEIN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALARIA VACCINES; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TH1 CELLS; VACCINES, DNA;

EID: 77953042787     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181d75cef     Document Type: Article

References (31)

1. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519-540.
2. Hung CF, Tsai YC, He L, et al. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther. 2007;15:1211-1219.
3. Kim D, Monie A, He L, et al. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+T cell immune responses. Gene Ther. 2008;15:677-687.
4. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci. 1997;60:163-172.
5. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000;18:927-974.
6. Hung CF, Yang M, Wu TC. Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol Med. 2006;127:199-220.
7. Tsen SW, Paik AM, Hung CF, et al. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007;6:227-239.
8. Kim TW, Hung CF, Ling M, et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest. 2003;112:109-117.
9. den Boer AT, Diehl L, van Mierlo GJ, et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol. 2001;167:2522-2528.
10. Allen TM, Vogel TU, Fuller DH, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol. 2000;164:4968-4978.
11. Kent SJ, Zhao A, Best SJ, et al. Enhanced T-cell immunogenicity and protective effcacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol. 1998;72:10180-10188.
12. Irvine KR, Chamberlain RS, Shulman EP, et al. Enhancing effcacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst. 1997;89:1595-1601.
13. Lin CT, Hung CF, Juang J, et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther. 2003; 8:559-566.
14. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-26.
15. Ji H, Wang TL, Chen CH, et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum Gene Ther. 1999;10:2727-2740.
16. Peng S, Ji H, Trimble C, et al. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol. 2004;78:8468-8476.
17. Kim TW, Hung CF, Boyd D et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol. 2003;171: 2970-2976.
18. Chen CH, Wang TL, Hung CF, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 2000;60:1035-1042.
19. Kim D, Hoory T, Wu TC, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell. Hum Gene Ther. 2007;18:1129-1139.
20. Medema JP, Schuurhuis DH, Bres SA, et al. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. JExpMed. 2001; 194:657-667.
21. Mueller SN, Jones CM, Stock AT, et al. CD4+ T cells can protect APC from CTL-mediated elimination. J Immunol. 2006; 176:7379-7384.
22. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184: 747-752.
23. Jaiswal AI, Croft MJ. CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response. J Immunol. 1997;159: 2282-2291.
24. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med. 1982;155: 768-782.
25. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+T lymphocytes. Nature. 2003;421:852-856.
26. Behrens GM, Li M, Davey GM, et al. Helper requirements for generation of effector CTL to islet beta cell antigens. J Immunol. 2004;172:5420-5426.
27. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature. 1998;394:482-485.
28. McMichael AJ. The original sin of killer T cells. Nature. 1998; 394:421-422.
29. Fujii S, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607-1618.
30. Ouaaz F, Arron J, Zheng Y, et al. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity. 2002;16:257-270.
31. Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. JExpMed. 2000;191: 495-502.